A Randomized, Double-blinded, Dose-escalation Phase Ia Study to Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
Latest Information Update: 14 Jun 2023
At a glance
- Drugs SCT 650C (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Sinocelltech
Most Recent Events
- 14 Jun 2023 New trial record